{"url_path":"/sec/cprx/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-290768-index.html","accession_number":"0001193125-26-290768","cik":"0001369568","ticker":"CPRX","issuer_name":"CATALYST PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-290768-index.html","primary_entity_key":"0001369568","primary_entity_name":"CATALYST PHARMACEUTICALS, INC."},"word_count":81,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\n \n(d)\n\nExhibits\n\n \n\n99.1\n \n[Press release issued by the Company on June 30, 2026.](d158010dex991.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n2\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\nCatalyst Pharmaceuticals, Inc.\n\nBy:\n \n\n/s/ Michael Kalb\n\n \n\nMichael Kalb\n\n \n\nExecutive Vice President and CFO\n\nDated: June 30, 2026\n\n \n\n3"}